Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective.
Two separate studies examined the controversial topic of prescribing statins to high-risk elderly patients who do not already have high cholesterol or cardiovascular disease.
Researchers focused on 22 pairs of identical twins for 8 weeks, asking one twin to follow a healthy vegan diet and the other to follow a healthy omnivorous diet.
Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
